Pharmaceutical

Anthony Fauci talked Covid in Congress in a nine-hour, ...

Anthony Fauci spent nine hours on Capitol Hill yesterday, talking Covid behind c...

STAT+: Pharmalittle: We’re reading about a GSK deal, a ...

GSK will purchase the asthma drug developer Aiolos Bio for $1 billion upfront, t...

STAT+: Nvidia says a biological revolution is happening...

Is now the moment when drug development, which for years has only gotten more di...

STAT+: JPM 2024: FogPharma’s new CEO, Mathai Mammen, un...

FogPharma CEO Mathai Mammen is taking the stage at #JPM24 Tuesday for what he’s ...

STAT+: Doudna institute hatches plan to ‘cure hundreds ...

The economics of CRISPR don't currently work for very rare diseases. The Doudna ...

HHS’s Xavier Becerra, once an ‘invisible’ secretary, is...

Health secretary Xavier Becerra, once ‘invisible,’ is finally making inroads wit...

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: L...

AUR-101 is under clinical development by Aurigene Oncology and currently in Phas...

Subasumstat by Takeda Pharmaceutical for Relapsed Multi...

Subasumstat is under clinical development by Takeda Pharmaceutical and currently...

FDA denies approval for Astellas’ investigational gastr...

Approval for zolbetuximab was quashed after the FDA found deficiencies in the co...

Zealand raises DKr1.45bn to advance obesity pipeline

The proceeds from the private placement will fund the development of Zealand’s o...

MSD acquires Harpoon for $680m to strengthen T-cell eng...

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology po...

Biocytogen and Radiance partner for bispecific antibody...

Biocytogen Pharmaceuticals and Radiance Biopharma have signed an exclusive optio...

BIOS Health to launch precision medicine centre in Cali...

BIOS Health has partnered with the City of Bakersfield, Kern County, and Kern Ve...

EC approves Pfizer’s Talzenna combo for prostate cancer...

The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults ...

Johnson & Johnson agrees to acquire Ambrx Biopharma for...

Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of...

HH-006 by Huahui Health for Hepatitis D: Likelihood of ...

HH-006 is under clinical development by Huahui Health and currently in Phase I f...